Non-small cell lung cancer (NSCLC) accounts for B80% of all lung cancers. Although some advances in lung cancer therapy have been made, patient survival is still quite poor. Two microRNAs, miR-221 and miR-222, upregulated by the MET proto-oncogene, have been already described to enhance cell survival and to induce TNF-related apoptosis-inducing ligand (TRAIL) resistance in NSCLC cell lines, through the downregulation of p27 kip1 , PTEN and TIMP3. Here, we further investigated this pathway and showed that miR-130a, expressed at low level in lung cancer cell lines, by targeting MET was able to reduce TRAIL resistance in NSCLC cells through the c-Junmediated downregulation of miR-221 and miR-222. Moreover, we found that miR-130a reduced migratory capacity of NSCLC. A better understanding of METmiR-221 and 222 axis regulation in drug resistance is the key in developing new strategies in NSCLC therapy.
Introduction
Non-small cell lung cancer (NSCLC) is the most frequent type of lung cancer and the most common cause of cancer death. Poor survival of NSCLC cases is in part due to the development of drug resistance. (Socinski et al., 2007) . TNF-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor family, known to induce apoptosis in a variety of different tumor types. Moreover, TRAIL is able to specifically induce cell death in cancer cells while sparing normal cells, and is currently tested as promising antitumor agent in clinical trials (Walczak et al., 1999) . Still many tumors, including NSCLC, are resistant to TRAIL and this limits its clinical application (Schaefer et al., 2007) . MiRNAs are small non-coding RNAs of 19-25 nucleotides that can inhibit mRNA translation and/or negatively regulate its stability (Ambros, 2004) . MiRNA dysregulation is one of the most important factors contributing to cancer development (Croce, 2009) . Recently, evidence for a role for microRNA in determining cancer drug resistance to therapy has emerged (Garofalo et al., 2009; Incoronato et al., 2010) . Several miRNAs are indeed involved in drug resistance, such as miR-15 and miR-16 that by targeting BCL-2 are involved in chronic lymphocytic leukemias (Cimmino et al., 2006) , miR-214, which by targeting phosphatase and tensin homolog, induce ovarian cancer progression (Yang et al., 2008) and miR-221 and miR-222, which are markedly upregulated in TRAIL-resistant compared with TRAIL-sensitive NSCLC cells (Garofalo et al., 2009) . In fact, miR-221 and miR-222, whose expression is regulated by MET through activator protein-1 (AP1) (Garofalo et al., 2009) , modulate TRAIL sensitivity in lung cancer cells mainly by interfering with p27kip1, PTEN and TIMP3 expression and TRAIL-induced caspase machinery (Garofalo et al., 2008 (Garofalo et al., , 2009 . MET is a membrane receptor for the hepatocyte growth factor/scatter factor (Birchmeier and Gherardi, 1998) . MET tyrosine kinase and its cognate ligand hepatocyte growth factor/scatter factor are known to promote survival of many cell types exposed to various apoptotic inducers, including serum starvation, death receptor activation or genotoxic treatment (Tulasne and Foveau, 2007) . MET is normally expressed by cells of epithelial origin and, upon hepatocyte growth factor stimulation, stimulates the invasive growth of cancer cells and increases their metastatic potential, principally through increased phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and JNK (Song and Moon, 2006) . Once activated JNKs phosphorylate the c-Jun proto-oncoprotein, which is known to participate in the formation of the AP1 transcription factor as a homodimer or heterodimer with c-Fos. (De´rijard et al., 1994) . In NSCLC and HCC, MET regulates miR-221 and miR-222 levels and, accordingly, cellular invasion and migration, through the c-Jun transcription factor and JNK activation (Garofalo et al., 2009) . In this study, we investigated the role of miR-130a in TRAIL resistance and tumorigenesis of NSCLC, focusing on miR-221 and miR-222 regulation induced by the MET oncogene.
Results

miRNA-130a targets the MET proto-oncogene
To better understand the role of miRNAs in drugresistance of lung cancer cells, we performed a bioinformatics search for putative miRNAs targeting MET. Among them, miR-130a was a very good candidate as it has been reported to be downregulated in NSCLC (Gao et al., 2010) , and has a seed region that matches the 3 0 -untranslated region (UTR) of human MET (nucleotides 4460-4467; NM_000245) ( Figure 1a ). To verify whether MET was a direct target of miR-130a, MET 3 0 -UTR, containing the miR-130a binding site, was cloned downstream of the luciferase open reading frame. This reporter construct was used to transfect A549 cells together with miR-130a. Introduction of miR-130a in A549 cells with the wild-type 3 0 -UTR construct had significant inhibition of luciferase activity as compared with the negative control ( Figure 1c) . As a control, increased expression of miR-130a in A549 cells was confirmed by qRT-PCR (Figure 1b) . Also, mutation of the miR-130a binding site within the MET 3 0 -UTR abolished the ability of miR-130a to regulate luciferase expression (Figures 1a and c) . Finally, enhanced expression of miR-130a in A549 cells strongly reduced MET endogenous protein and mRNA levels in A549 cells, as compared with control cells transfected with scrambled miRNA (Figures 1d and f) . Increased expression of miR-130a in transfected cells (Figures 1d and f) was miRNA-130a downregulates miRNA 221/222 expression through AP1 As the c-MET receptor is able to activate Akt and ERKs signaling (Peruzzi and Bottaro, 2006) , we analyzed Akt and ERK phosphorylation upon enhanced expression of miR-130a. As shown in Figure 2a , miR-130a overexpression decreased Akt and ERK1/2 phosphorylation levels in A549 lung cancer cells. The same effect was obtained by using a small interfering RNA (siRNA) MET (Figure 2a ). Increased miR-130a expression levels were also confirmed by qRT-PCR (Figure 2b ). Akt and ERK1/2 phosphorylation levels were also reduced in CALU-1 and H1299 NSCLC cell lines by miR-130a overexpression (Supplementary Figure 2a) . The same effect was obtained using siRNA MET (data not shown). Garofalo et al (2009) showed how MET is also implicated in miR-221 and miR-222 transcriptional regulation. Indeed, c-MET activation by growth factor is able to enhance miR-221 and miR-222 expression through JNK and AP1, in particular c-Jun, which directly binds an AP1-responsive element on miR-221 and miR-222 promoter region. In turn, miR-221 and miR-222 upregulation promotes apoptosis resistance and stimulates cellular migration (Garofalo et al., 2009) . Therefore, we decided to investigate miR-130a ability to modulate the miR-221 and miR-222 expression levels through AP1, by acting on MET expression. A Pgl3 basic construct carrying the AP1-responsive elements cloned upstream of the firefly luciferase coding region was used to test our hypothesis. After 24, 48 and 72 h of transfection of miR-130a in A549 cells, we observed Figure 2c we show that the discrepancy in percentage of miR-221 and miR-222 expression levels between scrambled miR and miR-130a in presence of siRNA c-Jun is less than using siRNA scramble control, these data reinforce the evidence that miR-130a-mediated suppression on miR-221 and miR-222 levels acts through AP1. We also performed a western blot to show the reduced levels of MET and c-Jun when miR130a and c-Jun siRNA, respectively, were transfected in A549 cells (Supplementary Figure 2d) . As a control, increased expression of miR-130a in A549 cells was confirmed by qRT-PCR (Supplementary Figure 2e) .
miRNA-130a activates apoptosis in NSCLC through miR221 and miR-222 downregulation MET receptor is able to directly recruit phosphoinositide 3-kinase through the two phosphorylated tyrosine residues of the C-terminal multi-substrates docking site (Fan et al., 2004) . The phosphoinositide 3-kinase pathway is involved in several biological responses mediated by MET activation, including cell survival (Fan et al., 2004) . We have previously shown that induction of miR-221 and miR-222 expression by the MET oncogene and c-Jun transcription factor leads to resistance to TRAIL-induced apoptosis (Garofalo et al., 2008) . To test whether miR-130a overexpression in resistant A549 cells leads to TRAIL-induced apoptosis through miR-221 and miR-222 downregulation, cells were exposed to TRAIL for 40 mins to induce cell death and poly (ADPribose) polymerase activation was assessed by western blot. After introduction of miR-130a, A549 cells resulted more sensitive to TRAIL death induction as shown by poly (ADP-ribose) polymerase activation ( Figure 3a) . In these cells, miR-221-enforced expression leads to a partial restoration of the TRAIL-induced resistance ( Figure 3a ). MiR-130a and miR-221 ectopic expression levels were investigated by qRT-PCR (Figure 3b ). Similar experiments have been performed also for miR-222 ( Supplementary Figures 3a and b) . To show that A549 TRAIL-induced apoptosis is depending on miR221 and miR-222, their endogenous expression levels were quantified by qRT-PCR. As shown in Figure 3c , miR-130a overexpression induced miR-221 and miR-222 downregulation also in A549 cells treated with TRAIL. A decrease of endogenous miR-221 and miR-222 expression levels in NSCLC cells resulted in increased TRAIL sensitivity (Garofalo et al., 2009) . To further confirm this data, we performed a proliferation assay in A549 cell lines with low levels of miR-130a expression and high levels of miR-221 and miR-222. Cells were exposed to TRAIL for 48 h and, then cell proliferation was assessed by using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cells expressing high levels of miR-130a showed a very low proliferation rate and underwent TRAILinduced cell death, whereas cells overexpressing high levels of miR-130a and miR-221 partially reacquired resistance when exposed to soluble TRAIL ( Figure 3d ). An equal proliferation assay has been performed also in CALU-1, H1299 and A459 NSCLC cell lines (Supplementary miRNA-130a modulates migration in NSCLC Several studies have shown that MET induces tumor cell migration and invasion through the activation of the phosphoinositide 3-kinase/AKT pathway (Segarra et al., 2006; Cecchi et al., 2010) . To test the effect of miR-130a on cellular migration, a 'scratch' assays was performed. A549 cells were first cultured in monolayer and then scratched after 48 h of transfection. Interestingly, miR130a overexpression significantly inhibited A549 cell ability to migrate (Figures 4a and b) . In the same cells, we observed decreased expression levels of miR-221 and miR-222 as compared with the control (Figure 4c ).
To support this finding, we also performed a transwell migration assay. This experiment confirmed our previous data showing that A549 cells overexpressing miR-130a had a lower capacity to migrate through the pores (Figures 4d and e) and presented lower levels of miR-221 and 222 as compared with the control (Figure 4f To better investigate the effect of miR-130a on migration in NSCLC, a transwell migration assay has been performed in A549 cells treated with a caspase inhibitor zVAD. We used a caspase inhibitor for this assay to make sure that the effect of miR-130a on migration in A549 cells was not correlated with the induction of apoptosis because of miR-130a overexpression. A549 cells were treated with 50 mm zVAD for 48 h and with dimethyl sulfoxide as control; a transwell migration assay has been performed. As shown in Supplementary Figures 4a and b , the effect of miR-130a on migration of A549 cells is not depending on caspase activity since the number of migrated cells treated with zVAD is comparable with his control. We also shown that treatment with zVAD do not interfere with miR-130a overexpression and also do not interfere with the effect that miR-130a has on miR-221 and miR-222 expression levels ( Supplementary Figures 4c and d) . To confirm the caspase inhibition in A549 cells by zVAD, a caspase 3/7 assay has been performed (Supplementary Figure 4e) .
Discussion
NSCLC accounts for B80% of all lung cancer cases, and remains an incurable disease (Ramalingam et al., miR-130a induces TRAIL-sensitivity in NSCLC M Acunzo et al 1998). One of the most important factors that affect survival rate is resistance to therapeutic drugs. TRAIL is considered a powerful anticancer therapeutic drug as it kills only the tumor cells without any cytotoxic effect to normal cells. (Wiley et al., 1995; Mariani et al., 1997) . Unfortunately, many human cancer cells remain resistant to TRAIL-induced apoptosis, but the mechanism of such resistance is still not clear. Recently, evidence of the role of microRNAs in drug sensitivity/resistance has been emerging. Garofalo et al. (2008) identified five miRNAs up-or downregulated in the TRAIL-resistant compared with the sensitive cell lines, and among them they found an upregulation of miR-221/222. Moreover, our group recently reported that the activation of miRNA-221 and miRNA-222 is regulated, at least in part, by the MET oncogene and c-Jun transcription factor. (Garofalo et al., 2009 ). Here we have further investigated this pathway and found that miR-130a was able to regulate miR-221 and miR-222 expression through MET downregulation. MiRNA-130a has been found to be downregulated in various chemoresistant tumor cells (Sorrentino et al., 2008; Hummel et al., 2010) . MET receptor promotes a complex biological program designated as 'invasive growth' that results from stimulation of cell motility, invasion and protection from apoptosis. Activation of MET signaling is a frequent event observed in many types of cancers, including lung, and its aberrant expression often correlates with poor prognosis in a variety of human malignancies. Interestingly, by bioinformatics search we found that the miR-130a induces TRAIL-sensitivity in NSCLC M Acunzo et al 3 0 -UTR of human MET contained regions that matched the seed sequence of miRNA 130a. By luciferase assays and western blots we confirmed MET as a direct target of miR-130a. We have previously shown that MET conferred resistance to TRAIL-inducing apoptosis regulating miRNA-221 and miRNA-222 levels (Garofalo et al., 2009) , and for this reason we investigated the effects of miR-130a on miR-221 and miR-222 expression. We found that miR-130a overexpression was able to reduce the cellular levels of miR-221/222 by reducing MET expression levels. Previously we showed how c-Jun, but not c-Fos, was involved in miR-221 and miR-222 activation, and that c-Jun had one binding site in the miR-221 and miR-222 promoter region. On this basis we investigated, by chromatin immunoprecipitation, ability of miRNA-130a to reduce the binding of c-Jun to the miRNA-221 and miRNA-222 promoter region and we found that miR-130a overexpression, as well MET downmodulation by siRNA, was able to reduce drastically this interaction. In fact, the effect of this loss of binding resulted in a downregulation of miR-221/222 expression. As miR-221/222 have been found involved in TRAIL resistance in NSCLC (Garofalo et al., 2009) we focused on the effect that the miR-130a may have on TRAIL resistance in these cells. Thus, we overexpressed miR-130a in TRAILresistant NSCLC cell lines and then we evaluated its effect on apoptosis after TRAIL treatments. We found that miR-130a was able to increase TRAIL sensitivity in NSCLC TRAIL-resistant cell lines. This finding highlighted how miR-130a, by targeting MET, was able to reduce miR-221/222 expression and, accordingly, TRAIL resistance in NSCLC cells. In fact, the data suggest that apoptosis induced by TRAIL in NSCLC cells is at least in part, dependent on miR-130a expression. It has been reported that downregulation of miR-221 and miR-222 resulted in a decrease of cell migration and invasion in both CALU-1-lung derived and Snu-387 hepatocarcinoma cells (Garofalo et al., 2009) . To understand the role of miR-130a on cellular migration induced by miR-221/222 two different migration assays were performed. MiR-130a overexpression in A549 and CALU-1 cells was able, by reducing miR-221/222 expression, to decrease the migratory abilities of cells and we also show how this effect is not dependent on apoptosis. Taken together the results suggested that miRNA-130a was able to modulate miRNA-221 and miRNA-222 expression by targeting MET, and this effect resulted in an improved TRAIL sensitivity and a decrease of cell migration in NSCLC cell lines. Thus, targeting MET and modulating miR-221/222 could be used not only to sensitize NSCLC to TRAIL-inducing apoptosis but also in the prevention and inhibition of lung cancer.
Materials and methods
Target analysis
Bioinformatics analysis was performed by using these specific programs: Targetscan (http://www.targetscan.org/), Pictar (http://pictar.mdc-berlin.de/) and RNhybrid (http://www. bibiserv.techfak.uni-bielefeld.de/).
Cell culture, transfection and chemicals A549, A459 and H1299 cells were seeded and grown in (RPMI) with 10% fetal bovine serum (FBS) and CALU-1 cells in Dulbecco's modified Eagle medium with 10% FBS, L-glutamine and antibiotics (Invitrogen, Carlsbad, CA, USA). All the transfections were performed by using Lipofectamine 2000 (Invitrogen), as suggested by the manufacturer. All cell lines utilized were cultured to 80% confluence in p60 plates with a serum-free medium without antibiotics and then transfected with 100 nmol of pre-miR 130a, pre-miR-221 and -222 oligonucleotides or negative control for 72 h (Ambion, Carlsbad, CA, USA). pGL3 control MET 3 0 -UTR, pGL3 control MET 3 0 -UTR mutated and pGL3 basic AP1-responsive elements were transfected as described later in 'Luciferase Assay' section.
Super-Killer TRAIL (Alexis Biochemicals, Plymouth, CA, USA) was used for 24-48 h at 400 ng/ml zVAD (caspase inhibitor) (RD System, Minneapolis, MN, USA) was used at a concentration of 50 mm for 48 h.
siRNA MET and siRNA c-Jun transfection A549 cells were cultured to 80% confluence and transiently transfected using Lipofectamine 2000 (Invitrogen) with siRNA met and siRNA c-Jun (Santa Cruz Biotechnology, Santa Cruz, CA, USA), as described in the manufacturer's protocol.
RNA extraction
Total RNA was extracted with TRIzol solution (Invitrogen) and the integrity of RNA was assessed with an Agilent BioAnalyzer 2100 (Agilent, Palo Alto, CA, USA).
Western blot analysis A549 cells (1 Â 10 5 ) were seeded and grown in RPMI with 10% FBS in six-well plates for 72 h. After transfection, cells were washed with cold phosphate-buffered saline (PBS) and subjected to lysis in a lysis buffer (50 mM Tris-HCl, 1 mM EDTA, 20 g/l SDS, 5 mM dithiothreitol, 10 mM phenylmethylsulfonyl fluoride). Equal amounts of protein lysates (50 mg each) and rainbow molecular weight marker (Bio-Rad Laboratories, Hercules, CA, USA) were separated by 4-20% SDS-PAGE and then electrotransferred to nitrocellulose membranes. The membranes were blocked with a buffer containing 5% non-fat dry milk in Tris-buffered saline with 0.1% Tween-20 for 2 h and incubated overnight with antibodies at 4 1C. After a second wash with Tris-buffered saline with 0.1% Tween 20, the membranes were incubated with peroxidase-conjugated secondary antibodies (GE Healthcare, Amersham, Pittsburg, PA, USA) and developed with an enhanced chemiluminescence detection kit (Pierce, Rockford, IL, USA). b-Actin was used as a loading control (Sigma, St Louis, MO, USA). ERK1/2, phosphorylated ERK1/2, MET were from Santa Cruz Biotechnology. Total Akt, phosphorylated Akt and poly (ADP-ribose) polymerase antibodies were from Cell Signaling Technologies (Danvers, MA, USA).
Transwell migration assay A549 cells were grown in RPMI containing 10% FBS to B60% confluence and transfected with 100 nM miR-130a, miR-221 precursor molecule or a negative control. After 48 h, the cells were harvested by trypsinization and washed once with Hank's balanced salt solution (Invitrogen). To measure cell migration, 8-nm pore size culture inserts (Transwell; Costar, High Wycombe, UK) were placed into the wells of 24-well culture plates, separating the upper and the lower chambers. In the lower chamber, 400 ml of RPMI 10% FBS miR-130a induces TRAIL-sensitivity in NSCLC M Acunzo et al was added. Then, 1 Â 10 5 cells were added to the upper chamber. After 24 h of incubation at 37 1C with 5% CO 2 , the number of cells that had migrated through the pores was quantified by counting 10 independent visual fields under the microscope (Zeiss, Thornwood, NY, USA) using a Â 10 objective and cell morphology was observed by staining with hematoxylin and eosin.
In vitro migration scratch Confluent A549s (passage o7) were transfected using Lipofectamine2000 (Invitrogen) with miR-130a, miR-221 or control oligonucleotides. At 48 h after transfection, a cell scratch spatula was used to make a scratch in the cell monolayer after which the cell monolayers were rinsed and further incubated. Pictures of the scratches were taken by using a digital camera system coupled to a microscope. The cells were incubated for 8 and 24 h, and pictures of the scratches were taken by using a digital camera system coupled to a microscope (Zeiss) using a Â 4 objective. To determine the migration distance (mm) we used a software image analysis program Image J (a version of NIH Image, http://rsb.info. nih.gov/ij/) as the reduction of the wide of the open area.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were carried out with an acetyl-Histone H3 immunoprecipitation assay kit (Upstate Biotechnology, Billerica, MA, USA) according to the manufacturer's instructions. Briefly, A549 cells were transfected with negative control miR, miR-130a, negative control siRNA or MET-siRNA, and, at 48 h after the transfection, cells were fixed in 1% formaldehyde for 10 min at 37 1C, washed with ice cold 1 Â PBS, scraped in 1 Â PBS plus protease inhibitors and collected by centrifugation. Cell pellets were resuspended in lysis buffer (Upstate Biotechnology) plus protease inhibitors and sonicated. Chromatin was immunoprecipitated using 2 mg of anti-c-Jun antibody (Santa Cruz Biotechnology) or normal rabbit immunoglobulin G as negative control. Immunoprecipitated chromatin was washed by following the manufacturer's instructions, and cross-links were reversed by treatment with proteinase K at 65 1C overnight. DNA was recovered by phenol/ chloroform extraction and resuspended in water. Input and immunoprecipitated DNA were analyzed by PCR to detect the presence of human or murine ATM promoter. PCR reactions were performed with AmpliTaq gold DNA polymerase (Applied Biosystems). The PCR products were separated on a 2% agarose gel, stained with ethidium bromide and scanned using a Typhoon 9200 scanner (GE Healthcare Biosciences, Pittsburgh, PA, USA). Primers used to amplify the sequence of promoters were described elsewhere (Garofalo et al., 2009) .
Luciferase assay
To generate hepatocyte growth factor receptor (MET) luciferase reporter constructs, the 3 0 -UTR was amplified by PCR and cloned downstream of the luciferase-coding sequence in the pGL3-control vector at the XbaI restriction site (Promega, Madison, WI, USA). Mutations were introduced into the miRNA-binding sites by using the QuikChange Mutagenesis Kit (Stratagene, La Jolla, CA, USA). A549 cells were transfected with Lipofectamine 2000 (Invitrogen), 500 ng of pGL3control containing MET 3 0 -UTR wild type (F: 5 0 -tctag agcctccttctgggagacatcatagtgc-3 0 ; R: 5 0 -tctagacttgtcactgcctatacc tgcagc-3 0 ) or MET 3 0 -UTR mutated (F: 5 0 -catcgatattctttgctctt gccaaaatattataggacttgtattgttatttaa-3 0 ; R: 5 0 -ttaaataacaatacaagt cctataatattttggcaagagcaaagaatatcgatg), 50 ng of Renilla luciferase expression construct. After 24 h, cells were lysed and assayed with Dual Luciferase Assay (Promega) according to the manufacturer's instructions. To study the role of AP1, we used a vector expressing the AP1-responsive elements cloned upstream the firefly luciferase coding region in pGL3-basic vector (Clontech, Mountain View, CA, USA). A549 cells were transfected with Lipofectamine 2000 (Invitrogen), 500 ng of pGL3-basic containing AP1-responsive elements, 50 ng of Renilla luciferase expression construct. After 24, 48 and 72 h, cells were lysed and assayed with Dual Luciferase Assay (Promega) according to the manufacturer's instructions.
Cell death and cell proliferation assay Cells were plated in 96-well plates in triplicate and incubated at 371 C in a 5% CO 2 incubator. Super-Killer TRAIL (Alexis Biochemicals) was used for 24-48 h at 400 ng/ml. Viability of cells was examined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Cell Titer 96 AQueous One Solution Cell Proliferation Assay (Promega), according to the manufacturer's protocol. Metabolically active cells were detected by adding 20 ml to each well. After 1 h of incubation, the plates were analyzed in a Multilabel Counter (Bio-Rad Laboratories). Apoptosis was assessed using Annexin V-FITC apoptosis detection kits followed by flow cytometric analysis and caspase 3/7 activity. Cells were seeded at 1.8 Â 10 6 cells per 100 mm dish, grown overnight in 10% FBS/RPMI, washed with PBS and then treated for 3 h with 400 ng/ml TRAIL. Following incubation, cells were washed with cold PBS and removed from the plates by trypsinization. The resuspended cells were washed with cold PBS and stained with FITCconjugated Annexin V antibody according to the manufacturer's instructions (Roche Applied Science, South San Francisco, CA, USA). Cells (5 Â 10 5 per sample) were then subjected to flow cytometric analysis. Flow cytometry analyses were carried out as described (Garofalo et al., 2009) . The fraction of A549 cells treated with TRAIL was taken as the apoptotic cell population. The percentage of apoptosis indicated was corrected for background levels found in the corresponding untreated controls. For detection of caspase 3/7 activity, cells were cultured in 96-well plates and treated with 400 ng/ml TRAIL and analyzed using Caspase-Glo 3/7 Assay kit (Promega) according to the manufacturer's instructions. The percentage of caspase activity was corrected for backgrounds levels found in the corresponding untreated controls.
qRT-PCR Real-time PCR was performed using a standard TaqMan PCR Kit protocol on an Applied Biosystem 7900HT Sequence Detection System (Applied Biosystems). The 10 ml PCR reaction included 0.67 ml RT product, 1 ml TaqMan Universal PCR Master Mix (Applied Biosystems), 0.2 mM TaqMan probe, 1.5 mM forward primer and 0.7 mM reverse primer, The reactions were incubated in a 96-well plate at 95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min. All reactions run in triplicate. The threshold cycle (C t ) is defined as the fractional cycle number at which the fluorescence passes the fixed threshold. The comparative C t method for relative quantization of gene expression (Applied Biosystems) was used to determine miRNA expression levels. The y axis represents the 2 (ÀDCt) , or the relative expression of different miRs. MiRs expression was calculated relative to U44 and U48 rRNA and multiplied by 10 4 . Experiments were carried out in triplicate for each data point, and data analysis was performed by using software (Bio-Rad).
Statistical analysis
Continuous variables are expressed as mean values ± s.d. The Student's t-test was used to determine the role of miRNAs miR-130a induces TRAIL-sensitivity in NSCLC M Acunzo et al expression on NSCLC cells in few experiments. Po0.05 was considered significant.
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